207 related articles for article (PubMed ID: 23605952)
41. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
Wang H; Xiao X; Xiao Q; Lu Y; Wu Y
Medicine (Baltimore); 2020 Jun; 99(24):e20094. PubMed ID: 32541448
[TBL] [Abstract][Full Text] [Related]
42. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
Kantarjian H; Faderl S; Garcia-Manero G; Luger S; Venugopal P; Maness L; Wetzler M; Coutre S; Stock W; Claxton D; Goldberg SL; Arellano M; Strickland SA; Seiter K; Schiller G; Jabbour E; Chiao J; Plunkett W
Lancet Oncol; 2012 Nov; 13(11):1096-104. PubMed ID: 23075701
[TBL] [Abstract][Full Text] [Related]
43. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
Azzariti A; Bocci G; Porcelli L; Fioravanti A; Sini P; Simone GM; Quatrale AE; Chiarappa P; Mangia A; Sebastian S; Del Bufalo D; Del Tacca M; Paradiso A
Br J Cancer; 2011 Mar; 104(5):769-80. PubMed ID: 21304529
[TBL] [Abstract][Full Text] [Related]
44. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
Zeremski V; Savić A
Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049
[TBL] [Abstract][Full Text] [Related]
45. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Boddu PC; Kantarjian HM; Ravandi F; Garcia-Manero G; Verstovsek S; Jabbour EJ; Takahashi K; Bhalla K; Konopleva M; DiNardo CD; Ohanian M; Pemmaraju N; Jain N; Pierce S; Wierda WG; Cortes JE; Kadia TM
Cancer; 2017 Aug; 123(16):3050-3060. PubMed ID: 28387922
[TBL] [Abstract][Full Text] [Related]
46. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
47. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Kantarjian HM; Roboz GJ; Kropf PL; Yee KWL; O'Connell CL; Tibes R; Walsh KJ; Podoltsev NA; Griffiths EA; Jabbour E; Garcia-Manero G; Rizzieri D; Stock W; Savona MR; Rosenblat TL; Berdeja JG; Ravandi F; Rock EP; Hao Y; Azab M; Issa JJ
Lancet Oncol; 2017 Oct; 18(10):1317-1326. PubMed ID: 28844816
[TBL] [Abstract][Full Text] [Related]
48. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M
Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555
[TBL] [Abstract][Full Text] [Related]
49. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo.
Oke A; Pearce D; Wilkinson RW; Crafter C; Odedra R; Cavenagh J; Fitzgibbon J; Lister AT; Joel S; Bonnet D
Cancer Res; 2009 May; 69(10):4150-8. PubMed ID: 19366807
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients.
Tangchitpianvit K; Rattarittamrong E; Chai-Adisaksopha C; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Tantiworawit A; Norasetthada L
Hematology; 2021 Dec; 26(1):355-364. PubMed ID: 33853503
[TBL] [Abstract][Full Text] [Related]
51. Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial.
Döhner H; Symeonidis A; Deeren D; Demeter J; Sanz MA; Anagnostopoulos A; Esteve J; Fiedler W; Porkka K; Kim HJ; Lee JH; Usuki K; D'Ardia S; Won Jung C; Salamero O; Horst HA; Recher C; Rousselot P; Sandhu I; Theunissen K; Thol F; Döhner K; Teleanu V; DeAngelo DJ; Naoe T; Sekeres MA; Belsack V; Ge M; Taube T; Ottmann OG
Hemasphere; 2021 Aug; 5(8):e617. PubMed ID: 34350385
[TBL] [Abstract][Full Text] [Related]
52. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
[TBL] [Abstract][Full Text] [Related]
53. Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
Natarajan-Amé S; Park S; Ades L; Vey N; Guerci-Bresler A; Cahn JY; Etienne G; Bordessoule D; Ravoet C; Legros L; Cheze S; Stamatoullas A; Berger E; Schmidt A; Charbonnier A; Chaury MP; Braun T; Fenaux P; Dreyfus F;
Br J Haematol; 2012 Jul; 158(2):232-237. PubMed ID: 22571447
[TBL] [Abstract][Full Text] [Related]
54. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
Dennis M; Russell N; Hills RK; Hemmaway C; Panoskaltsis N; McMullin MF; Kjeldsen L; Dignum H; Thomas IF; Clark RE; Milligan D; Burnett AK
Blood; 2015 May; 125(19):2923-32. PubMed ID: 25805811
[TBL] [Abstract][Full Text] [Related]
55. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
[TBL] [Abstract][Full Text] [Related]
56. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome.
Burnett AK; Hills RK; Hunter A; Milligan D; Kell J; Wheatley K; Yin J; McMullin MF; Cahalin P; Craig J; Bowen D; Russell N
Leukemia; 2011 Jul; 25(7):1122-7. PubMed ID: 21475252
[TBL] [Abstract][Full Text] [Related]
57. Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.
Webster JA; Tibes R; Morris L; Blackford AL; Litzow M; Patnaik M; Rosner GL; Gojo I; Kinders R; Wang L; Doyle LA; Huntoon CJ; Karnitz LM; Kaufmann SH; Karp JE; Smith BD
Leuk Res; 2017 Oct; 61():108-116. PubMed ID: 28957699
[TBL] [Abstract][Full Text] [Related]
58. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
Walsby E; Walsh V; Pepper C; Burnett A; Mills K
Haematologica; 2008 May; 93(5):662-9. PubMed ID: 18367484
[TBL] [Abstract][Full Text] [Related]
59. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner H; Weber D; Krzykalla J; Fiedler W; Kühn MWM; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Fransecky L; Koller E; Wulf G; Schleicher J; Ringhoffer M; Greil R; Hertenstein B; Krauter J; Martens UM; Nachbaur D; Samra MA; Machherndl-Spandl S; Basara N; Leis C; Schrade A; Kapp-Schwoerer S; Cocciardi S; Bullinger L; Thol F; Heuser M; Paschka P; Gaidzik VI; Saadati M; Benner A; Schlenk RF; Döhner K; Ganser A;
Lancet Haematol; 2023 Jul; 10(7):e495-e509. PubMed ID: 37187198
[TBL] [Abstract][Full Text] [Related]
60. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]